This pilot trial studies how well 3-dimensional (3D) contrast-enhanced ultrasound imaging works in diagnosing participants with liver cancer who are undergoing stereotactic ablative radiotherapy. Diagnostic procedures, such as 3-dimensional contrast-enhanced ultrasound, may help to determine whether perfusion characteristics (how blood flows to the liver over time) of liver metastases may be predictive of response to treatment and whether liver perfusion characteristics can be used to follow response to treatment.
Additional locations may be listed on ClinicalTrials.gov for NCT02424955.
See trial information on ClinicalTrials.gov for a list of participating sites.
PRIMARY OBJECTIVES:
I. Determine the feasibility and reproducibility of 3D contrast enhanced ultrasound imaging in liver cancer patients undergoing stereotactic ablative radiotherapy.
II. Evaluate whether there are treatment induced early changes in imaging metrics derived from 3D contrast enhanced ultrasound.
SECONDARY OBJECTIVES:
I. Evaluate the feasibility of contrast-enhanced ultrasound-to-computed tomography (CT) fusion by assisting three-dimensional (3D) perfusion ultrasound (US) imaging with optical and electromagnetic tracking of the ultrasound probe on patients with liver cancer that will undergo CT for treatment planning and/or response evaluation.
OUTLINE:
Participants receive perflutren intravenously (IV) over 6-8 minutes and undergo 3D contrast-enhanced ultrasound over 30 minutes: prior to standard of care stereotactic ablative radiotherapy (SABR), at 0-7 days after first SABR treatment, and then at 2-4 months in the absence of disease progression or unacceptable toxicity.
After completion of study, participants are followed up periodically.
Trial PhaseNo phase specified
Trial Typediagnostic
Lead OrganizationStanford Cancer Institute Palo Alto
Principal InvestigatorDaniel T. Chang
